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I. Introduction 
In considering transplantation immunology therc is obviously a major 
overlap with each of the other chapters in this volume. As long as this 
fact is acknowledged, there should be a real advantage in summarizing 
the immunology of transplantation from the clinician's point of view. 
In particular, it is worth focusing upon certain phenomena that have 
been seen after whole-organ transplantation, which form the basis for 
the clinical discipline of transplantation but which have not yet been 
precisely and satisfactorily explaincd by those interested in the definition 
of mechanisms. 
Major progress toward organ transplantation has been achieved only 
in the past few years. Before then an almost total ignorance of the 
biological problems that would be encountered after transplantation pre-
cluded the development of appropriate methods of therapy. As reccntly 
as 1940, there \vas still a widespread belief that application of tissue 
transplantation needed only the refinemcnt of better surgical techniques. 
Despite the slow accumulation of evidence that this was not the case, 
the situation remained obscure until the first of the studies by Sir Peter 
Medawar and his colleagues in England. 
A. MEDA WAR AND THE TURNING POINT 
~cdawarDs investigations were conceived and executed under trying 
circumstances. Questions concerning skin replacement had become more 
urgent than ever because of the nced to treat mass wartime casualties 
from the Battle of Britain. Thc answers were provided on the basis 
of investigation with rabbits in which the genetic homogeneity of the 
donor and recipient animals was sufficient to permit a reasonable repro-
ducibility of results. The conclusions were precise and can readily be 
summarized as they apply to humans. 
First, skin grafts placed with perfect surgical technique were rejected 
after a rather prcdictable interval which in the rabbit system was about 
10 days. In humans the rejcction time is highly variable, but within 
a few days to several weeks, repudiation of skin grafts is ordinarily 
complete in that initially viable skin becomes a blackened and necrotic 
eschar. 
In Medawar's report there was evidence that the repudiation was 
due to an immunological reaction of the host to the foreign tissue. Thc 
key observatioll in support of this concept was the fact that a second 
skin graft from the original rabbit donor strain was destroyed in an 
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accelerated fashion, suggesting the acquisition of immunity by the host. 
The immunity conferred by contact with the first graft ,vas permanent 
or of long duration and pertaincd to all tissues subsequently transplanted 
from the donor strain. The sensitization was specific inasmuch as grafts 
from other donor strains werc not usually rejected in an accelerated 
manner. The initial delay lwtwecn the actual transplantation and the 
subsequent development of active immunity prompted comparison 
between these events and the delayed h:'persensitivity that permits im-
munity to develop to diseases such as tuberculosis. 
B. NOMENCLATURE 
The terminology used in transplantation is based upon genetic and 
phylogenetic relationships which, in turn. roughly determine the hostility 
with which a graft is yiewed by its recipient. When tissue is transplanted 
from one location to another place on the same person (an autograft), 
it is identified as "self" (Fig. 1) and therefore does not eH)ke a defensive 
host reaction. The success or failure of the graft is excluSively dependent 
upon the technical adequacy of the procedure and upon other well-ac-
cepted principles of surgical care. 
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Fig. 1. Fundamental difference between auto grafts (left) and homo grafts (right). 
Tissues transferred bctween identical b\'ins behave as autografts. They are termed 
isografts and are not rejected. [From SIlJ'g. CUn. N. Amer. 42, 55 (1962); by per-
mission of W. B. Saunders Co.l 
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The same applies whcn tissues or organs are exchanged betwcen 
identical twins. These are called isografts. Because there is total genetic 
identity of identical twin donors and recipicnts, the grafts are not recog-
nized as foreign and can bc cxpectcd to have the same life expectancy 
as that of the host. This was first proved in man by Dr. J. B. Brown 
of St. Louis with skin transplantation experiments, reported in Surgery 
in 1937, and latcr applied to the transplantation of kidneys and, more 
recently, bone marrow between identical twins. 
Tissue transplantecl from nonidentical members of the same species 
(Fig. 1) are called homo grafts (or allografts). The host response that 
follows is defined above as rejection, the intensity of which is roughly 
determined by thc degree of gcnetic (lissimilarity between donor and 
recipient. The gcnetic factors of transplantation, often referred to as 
Snell's laws (after Dr. George Snell) were precisely worked out in inbred 
rodent experiments. Unfortunately, in the outbrcd canine and human 
populations, there is a tremcndous and as yet unpredictable variability 
in the vigor of the attack a homograft elicits. Thcse observations have 
led to an intensive search for methods that would allow identification 
of a favorable donor-recipient combination in advance of clinical trans-
plantation. These techniques are referrcd to as tissue typing, a subject 
to which we return later (see Section VII). 
If transplantation is from a donor belonging to a different but similar 
species, the tissue is called a heterograft, and on the average the rapidity 
and intensity of rejection arc eyen greater than with homografts. How-
ever, studies with chimpanzee to human heterografts pioneercd by Dr. 
Keith Reemtsma have shown that such transplants can sometimes be 
tolerated for long periods in patients receiving immunosuppressive 
therapy. 
Tissucs or organs transferred between Widely diyergent spccies (as, 
for example, between pigs and dogs) are called xenografts. In most in-
stances xenografts are destroyed within a few hours by a kind of hyper-
acute rejection \vhich is apparently snbserved by preformcd hetero-
specific humoral antibodies (see Section Il,C,3). 
II. Mechanisms of Rejection 
A. CELL-MEDIATED IM,\1UN1TY 
The Jlleans by which transplanted tissues and organs arc rejected 
are poorly understood. There has been abundant evidence that lympho-
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cytes participate in the process in an important way. This was illustrated 
by experiments of the late Dr. Glenn Algire, who used Millipore 
chambers in which enclosed fragments of tissue were shielded by a 
mesh barrier of appropriate sized interstices to exclude lymphocytes 
and othcr mononuclear cells but through which barrier nutrient fluid 
and even red cells could pass (Fig. :2). Survival of the transplants was 
longer than with tissue that was not thus protected. Corneal homo grafts, 
\vhich have been used clinieally for many years, presumably escape 
rejection at least partially for similar reasons; their nutrition is obtained 
from the cell-free aqueous humor in the anterior chamber of the eye. 
If a corneal graft becomes revascularized, it usually fails. 
The participation (if not the precise action) of mononuclear cells 
in the rejection of tissues and organs can be appreciated in a more 
direct way by histopathological studies. As the graft is repudiated, the 
normal architectural organization becomes distorted as variable necrosis 
develops (Fig. 3). At about the same time, massive infiltration by 
lymphocytes and plasma cells oeeUl's. It is not hard to understand how 
the liver in Fig. 3 nearly ceased to fUllction 6 days after its transplanta-
tion to an unmodified caninc recipient. Eventually, the blood supply 
to whole-organ grafts is diminished and later all but cut off, so that 
more-or-less complete ischemic necrosis is the ultimate fate of the trans-
plant if the recipient animal lives long enough for this stage to be 
reached. 
The hallmarks of classic unmodified cellular rejection are much the 
same in all acutely rejecting organs, whether they be liver, kidney, heart, 
skin, or others. The tissues become overrun with millions of lymphocytes 
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Fig. 2. Diffusion chamber experiment, after Algire. The enclosed homograft, which 
is protected from physical contact with lymphocytes, can survive for protracted 
periods. [From Surg. Clin. N. Amer. 42, 55 (1962); by permission of W. B. 
Saunders Co.] 
80 THOMAS E. STARZL AND CHARLES W. PUTNAM 
Fig. 3. Untreated canine hepatic hOll1ograft at 6 days. Portal vcins (P) and 
central vein (C) are surrounded bv a dellS'" infiltrate of mononuclear cells. There is 
('cntriloblllar necrosis with hC!l1orrl;age. The c\'(oplasm of the surviving hcpatoC'\'tcs 
in the middle and peripheral zones of the lobules contains abundant lipid. 
Hematoxylin and eosin stain. X27. The photolllicrograph was prepared by Dr. K. A. 
Porter, London, England. (From Advan. Surg., 196fJ; by permission of Yearbook 
Publishers, Inc.) 
and plasma cells. There is concomitant necrosis of thc distinctive 
parenchymal tissues that give the grafts their structural identity. 
B. HUMORAL A"TIBODIES 
There is no reason to believe that the cellular immune response is 
the only means by which delayed homograft rejection can occur. In 
the serum of patients undergoing acute rejection, cytotoxic or other 
kinds of antibodies han~ been described. Even in the serum of paticnts 
who have tolerated renal homo grafts for years, therc are often circulating 
antigraft antibodies, but in thcse cases apparently with a low capacity 
to cause transplant injury. Nevertheless, homografts in such recipients 
commonly contain deposits of y-globulin, as well as host complement. 
Antibody deposition has been very well documented after transplanta-
tion of human kidneys, livers, hearts, and lungs. The patterns of the 
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immunoglobulin binding are particularly interesting in renal grafts since 
they resemble those of two major kinds of experimental glomerulo-
nephritis, namely, Masugi nephritis caused by anti-GBM antibody, and 
the kind of nephritis caused by the filtration by the kidney of soluble 
antigen-antibody complexes. In many cases the glomerulonephritis in 
these transplants has been similar or identical to that which destroyed 
the native kidneys, indicating a recapitulation of the original disease. 
However, it may also be said that glomerulonephritis can be one mani-
festation of humoral homograft rejection. This position has received 
support from the fact that "glomerulonephritis" has been observed in 
homo grafts transplanted to recipients whose renal failure was due to 
polycystic kidney disease, cystinosis, pyelonephritis, or other disorders 
not suspected to be of autoimmune etiology. 
In other organs, such as the liver, immunoglobulin deposits have been 
somewhat less extensive than in renal homografts, and they have tended 
to be unevenly distributed throughout the vasculature. 
C. PRESENSITIZATION STATES 
1. Second-Set Reiection 
In Medawar's original experiments, which were mentioned earlier, 
skin transplanted to rabbits sensitized by one exposure to donor tissue 
was rejected in an accelerated, or second-set fashion. Instead of being 
repudiated after an average of 10 days, this time was shortened to 6 
days. The assumption was (and still is) that lymphoid tissue or other 
contributors to cell-mediated immunity are mobilized more quickly than 
normal because of their prior anti donor instruction. An additional role 
of Circulating humoral antibodies may also be important, and in more 
extreme degrees of sensitization these antibodies may come to be the 
dominant factor in what has been called hyperacute rejection (Section 
II,C,2). 
After whole-organ transplantation under immunosuppression, there 
have been numerous reports of accelerated rejection apparently com-
parable to that in Medawar's rabbit system. It has been speculated that 
the advance sensitization in these humans could have been induced 
to antigens also found in donor tissues, during the course of pregnancies, 
by the previous administration of white cells or platelets in multiple 
blood transfusions, or by other means including prior renal homotrans-
plantation. In such patients rejection occurs earlier and often more vigor-
ously than expected, but it does not necessarily proceed to immediate 
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Fig. 4. Development of a rejection crisis less than 36 hours posttransplantation. Al-
though transient anuria resulted, the process was reversed after the addition of high-
dose prednisone therapy. Note that a dialysis (D) was required before adequate 
function returned. Each arrow represents 200 p.g actinomycin C administered intra-
venously. This patient, whose transplant operation took place on July 8, 1963, still 
has excellent function of the same homograft almost U~ years later. It is probable 
that presensitization had occurred in this case and that the violent and early crisis was 
a second-set or accelerated rejection. [By pern1ission of Surg., Gynecol. Obstet. 118, 
819 (1964).] 
destruction of the graft. Reversal of this kind of uncomplicated accel-
erated rejection has often been observed (Fig. 4). 
2. Preformed Antibodies and Hyperacute Homograft Reiection 
a. ABO Incompatibility. The first clear examples of hyperacute rejec-
tion of renal homo grafts were in patients who received kidneys from 
ABO blood group-incompatible donors. An effective blood flow to some 
of these transplants was not restored when the vascular anastomoses 
were opened. The small vessels of the excised kidneys were demonstrated 
by angiography to be closed and, histopathologically, the arterioles and 
capillaries were plugged with formed blood elements, particularly 
erythrocytes. A rational although partial immunological explanation was 
available since the blood group substances that allow red cells to be 
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typed had been shown by Hagman and Szulman also to be found in 
other tissues including the kidneys. Consequently, if the kidney of an 
A, B, 01' AB donor were placed in a patient whose serum contained 
naturally occurring anti-A and/or anti-B isoagglutinins (an example 
would be a recipient with 0 blood type who would have both kinds 
of isoagglutinins), these antibodies might be predicted to bind with 
the renal red cell antigens. Serological studies in some of our cases 
showed that falls in systemic isoagglutinin titers actually occurred. Sub-
sequent investigators have reached similar conclusions about the role 
of red cell isoagglutinins in precipitating accelerated rejections. The 
rules of red cell compatibility as they apply to whole-organ transplanta-
tion are summarized in Table I. 
h. Cytotoxins and Other Antibodies. It is unlikely that future organ 
transplantations will be carried out under the foregoing adverse condi-
tions of ABO mismatching. However, hyperacute rejection in the 
presence of red cell group compatibility has been seen with increasing 
frequency and, in fact, this kind of rejection has become the chief cause 
of acute homograft loss in most major transplantation centers. The first 
case was described by Dr. Paul Terasaki of Los Angeles in a patient 
whose serum contained lymphocytotoxic antibodies that killed donor 
cells. Terasaki theorized that, in the course of being transfused prior 
to operation, the recipient had been immunized (probably on multiple 
occasions) to white cells that shared histocompatibility antigens with 
the eventual renal donor. Since then, no one has seriously challenged 
this general hypothesis of presensitization. The concept has been in-
directly supported by the high rate of hyperacute rejection with retrans-
plantation in patients whose first homo grafts were rejected and who 
were thereby presumably immunized to some antigens also present in 
the second graft. 
TABLE I 
DIRECTION OF ACCEPTABLE MIS-
MATCHED qfppr~; TRANSFERa 
o to non-O 
Rh- to Rh+ 
Rh+ to Rh-
A to non-A 
B to non-B 
AB to non-AB 
Safe 
Safe 
Relatively safe 
Dangerous 
Dangerous 
Dangerous 
a 0 is universal donor; AB is universal 
recipient. 
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Subsequently, many other investigators have confirmed the adverse 
implications of preformed anti donor antibodies as detected with several 
techniques. The most commonly cmployed mcthods have measurcd 
lymphocytotoxins and leukoagglutinins but, according to G. M. Williams 
and Felix Milgrom, the most scnsitive examination is the mixed ag-
glutination test. 
While certain tests may be more sensitive than others for the detection 
of the preimmunized state, it does not seem likely that a single antibody 
will be found to have unique predictive significance. In our laboratories 
deliberate scnsitization of dogs by repeated skin grafts led to the forma-
tion of a variety of antiwhite cell and antired cell antibodies with anti-
donor reactivity. Howevcr, the titer of thcse antibodies is not well cor-
related with the rapidity of rejection of a kidney from the skin donor. 
Moreover, it has been emphasized in rcports of clinical cases that hyper-
acute rejection presumably due to presensitization may occur even 
though antidonor antibodies cannot be found \vith any currently avail-
able techniquc including the mixed agglutination method. Under these 
circumstances it has been neccssary to assume that an immediate, albeit 
undiscernible, immunological reaction is thc initiating event in the 
destructive process that follows. With or without demonstrable anti-
bodies in the recipient scrum, the immunoglobulin deposition in the 
transplants may be in such small quantities that their specificity as 
judged by strictly morphological criteria in immunofluorescence studies 
could be opcn to question even though on other grounds it is reasonable 
to believe they are significant. 
c. Coagulation. A simplistic view of hyperacute rejection might be 
that the anti donor antibodies discussed in the preceding section were 
destructive of renal homografts h:' their direct nephrotoxicity. The ob-
servations already cited in the ABO-incompatible cases were not con-
sistent with such a conclusion since the most obvious lesion in the rapidly 
repudiated kidneys was occlusion of their blood supply by clot and 
mechanical debris including formed blood clements. 
In cases with hyperacute rejection despite red cell compatibility, there 
was also evidence of interference with the blood supply. When Kiss-
meyer-Nielsen described the histopathology of two hypcracutely rejected 
kidneys, he noted that the glomerular capillaries ancI the arterioles were 
full of microthrombi, making the morphological features indistinguish-
able from those of a generalized Shwartzman reaction. Similar observa-
tions were made in our own first cases (Fig. 5). 
Although these histopathological findings suggested that coagulation 
changes had occurred, clotting studies were not available to determine 
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Fig. 5. A glomerulus stained for fibrin from a homograft that had undergone hyper-
acute rejection. There is complete obliteration of the glomerular architecture with 
fibrin. X300. The photomicrograph was prepared by Drs. Richard A. Lerner and 
Frank J. Dixon. [By permission of N. Engl. J. Med. 278, 642 (1968).] 
if the alterations were systemic or if they were confined to the actual 
homograft. The first efforts to obtain such information were completely 
negative. 
More recently, evidence had been found that coagulation changes 
are an integral feature of hyperacute rejection in the presensitized canine 
model as well as in man. In the dogs that were exposed to multiple 
skin grafts from the eventual organ donor, the subsequently transplanted 
kidney, spleen, or liver always consumed clotting factors and platelets 
locally. One of the objectives of these animal investigations was to see 
if transplantation of consecutive organs from the same donor would 
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mitigate the rejection of the second graft. It was found that the second 
transplant was briefly protected, possibly by the prior depletion of either 
humoral antibodies, clotting factors, or formed blood elements. In time, 
however, the final organ suffered the same fate as the first one. 
All of the scnsitized caninc recipients in thc above study developed 
evidence of local consumption. In addition, a minority of animals also 
had profound systemic coagulation changes similar to those of dis-
seminated intravascular coagulation (DIC). Thc same kinds of observa-
tions have been made in patients after renal homotransplantation with 
a consequent severe or evcn fatal bleeding diathesis. Thus although 
the clotting abberations of hyperacute rejection are usually confined 
to the graft insofar as can be measured, there is now little reason to 
doubt that profound systemic changes may follow. 
d. Formed Blood Elements. White cells, platclcts, and red cells form 
a morphologically prominent component of the vascular plugs of hyper-
acutely rejecting renal homo grafts. vVilliams and Hume of the Medical 
College of Virginia were the first to draw attention to the dramatic 
appearance of polymorphonuclear leukocytes (PMN s) in such kidneys. 
Their observations, since amply confirmed, werc made possible by sys-
tematically biopsying homo grafts about 1 hour after revascularization. 
In some instances the PMNs appeared before any other histopathological 
findings werc evident. That thc participation of these cells in the ultimate 
destruction was not immunologically specific has been illustrated by 
experiments showing that autologous PMNs were effcctive intermediaries 
of hyperacute rejection. 
e. Interlocking Relationships. In sensitized recipients it is clear that 
a transplanted kidney almost immediately bccomes a trap for antidonor 
antihodies, formed blood clements, and clotting factors. The removal 
of these various substanccs occurs essentially simultaneously. Neverthe-
less, it must be assumed that an antigen-antibody reaction induces the 
clotting process, presumably with thc collaboration of PtvINS. 
f. Therapeutic Possibilities. Although clotting is prominent in the 
pathogenesis of hyperacute rejection, the use of potent anticoagu-
lants, including heparin and cobra snakc venom, have not provided effec-
tive prophylaxis. In contrast, the intraarterial infusion of either citrate 
or ethylenediaminc tetraeetie acid (EDT A) is of great bencfit, appar-
ently secondary to caleium bill ding. Calcium has an essential role in 
the clotting process, but it is also vital to the activation of complemcnt. 
Since citrate and EDTA therapy imposc predictably high risks under 
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the laboratory conditions tested so far, these drugs have not yet been 
used clinically. 
Within the last few months, Kobayashi of Boston has reported some 
potentially practical experiments in which organ pretreatment was 
carried out prior to transplantation. Monkey kidneys were perfused with 
pepsin-digested F ( ab ) 2 fragments made from the serum of an animal 
specifically sensitized against the organ donor. The noncomplement bind-
ing immunoglobulin fragments prevented the subsequent hyperacute 
rejection of these organs after transplantation to the sensitized original 
serum donors. 
3. Hyperacute Xenograft Rejection 
In recent years it has been thought, on the basis of indirect evidence, 
that the violent rejection occurring after xenotransplantation between 
divergent species was initiated by the action of preformed heterospecific 
antibodies. Support for the hypothesis included the fact that antidonor 
antibodies of several kinds were often demonstrable by preoperative 
in vitro testing of the recipient animals' sera, that such antibodies were 
cleared by organs transplanted from that donor, that the vascularization 
of successive kidneys from the same donor (or donors of the same 
species) usually prolonged the function of the last organ, presumably 
by antibody depletion, and that phYSiochemical removal of immuno-
globulins or the inactivation of complement in the recipient sometimes 
increased heterograft survival. 
It has been of considerable interest to compare the events of hyper-
acute xenograft rejection to those that abruptly lead by unquestionably 
immunological mechanisms to the destruction of homo grafts placed in 
recipients deliberately sensitized to donor tissue (see Section II, C,2) . 
The observations have been so similar in each circumstance that progress 
in ameliorating hyperacute rejection would be expected to be applicable 
to both situations. This prediction has been strikingly fulfilled in that 
both the citrate and EDT A therapy described in the preceding section 
can prevent the rejection of porcine-to-canine renal grafts for as long 
as ! day. Such kidneys fail within 2-10 minutes if untreated. 
III. Physiological Consequences of Classic Rejection 
The result of whole-organ rejection in untreated recipients is a rather 
sudden and progressive decline in the function of a homograft after 
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Fig. 6. The biochemical changes nsnally seen after orthotopic liver transplantation 
to an untreated recipient. A brief period of good function follows operation, but 
deterioration of the biochemical pattern is unrelenting once it has begun. (From 
Advan. Surg., 1966; by permission of Yearbook Publishers, Inc.) 
an initial interval of satisfactory performance. These typical events can 
be seen in the canine experiment summarized in Fig. 6. The recipient 
dog's own liver was removed and replaced with a homograft from a 
nonrelated donor. After several days of quite normal postoperative func-
tion, progreSSive jaundice developed. Not long after, astronomical in-
creases in serum transaminase indicated massive necrosis of hepatocytes 
just before the death of the animal. 
Of course, the same sequence of events occurs after transplantation 
of the kidney, heart, lung, and all other organs, with eaSily imagined 
variations according to the function of the organ in question. After ap-
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proximately the same dclay, host immune defenses are brought to bear 
upon the homografts. Then thc anatomic features of the tissues become 
distorted, the blood supply is choked off, and rejection usually goes 
on to completion in which case necrosis is the eventual consequence. 
The full evolution of classic whole-organ homograft rejection is essen-
tially always seen in untreated recipicnts if there is a strong natural 
histocompatibility barrier as there is, for example, between most (al-
though not all) nonrelated dogs or bctween nonrelated people. In con-
trast, rejection may be minor and/ or atypical if there is a weak barrier. 
In outbred animals a special example has been provided in pigs. Profes-
sor Henri Garnier of Paris first showed that livers transplanted in pigs 
did not evokc a very strong reaction despite the fact that no immuno-
suppression was given. It was promptly confirmed by Peacock and 
Terblanchc in Bristol, CaIne of Cambridge, and in our laboratories that 
clinically evident hepatic rejection sometimes never occurred cven when 
different breeds of pigs were used, or that on other occasions rejection 
could dcvelop and recede spontaneously. It has been proposed by CaIne 
that thcse results are due to some special tolerance-inducing substancc 
released by the liver. However, Perper and his associates have shown 
that thc pig is also a very "casy" animal in which to transplant the 
kidney, since long-term function of renal homo grafts can be obtained 
with only a day or two of immunosupprcssion or even with such minor 
manipulations as prOViding a coincident transfusion with donor blood. 
The Significance of the pig model is discussed further in Section V. 
IV. Immunosuppression 
A. A THEORETICAL IMPASSE? 
For scveral years after the features of rejection were defined, the 
not unreasonable assumption was made that this process was one of 
nature's most powerful and perscrvering rcactions which could be pre-
vented only by relatively complete crippling of the host's immune de-
fenses. In view of the evident connection between the capacity to mount 
an effective rejection and to rcact forcibly against a variety of other 
inimical environmental antigcns, including those of pathogenic micro-
organisms, the possibility of achieVing chronic graft survival without 
killing the host was seriously questioned. 
The first clue that host death was not the requisite penalty for homo-
graft protection came from the observations that permanent acceptance 
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of adult donor tissue could be induced in fetuses or newborn animals. 
The initial disclosure was made by Dr. Roy Owen, who noted that 
dizygotic calf siblings, whose circulation in utero communicated freely, 
could have each others white cells anel reel cells persist indefinitely after 
birth. These are known as the freemartin experiments of nature (Fig. 
7). 
On the basis of Owen's observations, Burnet of Australia suggested 
that exposure of the fetus to donor tissue might Similarly confer protec-
tion persisting after birth to slIbsequent grafts from the same donor 
but not to those from other donors. The hypothesis was confirmed by 
Billingham, Brent, and Medawar by injecting adult lymphOid cells into 
mousc fetuses. The experiments were later extended to other species. 
'While of no practical clinical valuc, these remarkable observations 
were of great theoretical interest. They appeared to be the result of 
exposing the host to donor antigens at a time when its immune mech-
anism was too rudimentary to recognize the graft tissue as foreign. After 
maturation of the immune mechanism, neither the graft nor other tissues 
from the same donor were identified any longer as alien. The observa-
tions indicated the feasibility of inducing acquired tolerance, and thereby 
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Fig. 7. Chimerism in cattle siblings. There is cross-tolerance to formed blood 
clements and to subsequently placed homo grafts as the result of intrauterine circula-
tory communication. [From Surg. CUn. N. Amer. 42, 55 (1962); by permission of 
W. B. Saunders Co.] 
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stimulated the search for immunosuppressive agents with which it was 
hoped that a similar sequence of events could be duplicated in adult 
recipients. 
Total body irradiation was the first kind of therapy demonstrated 
to prolong the life of homo grafts in adult animals. However, the treat-
ment was dangerous, requiring doses sufficient to cause bone marrow 
depression. There was a consequent acute mortality which was so exces-
sive that clinical organ transplantation proved to have little chance of 
success from the years 1957 to 1962 during which total body irradiation 
was given several clinical trials. Nevertheless, there were two patients 
trcated before 1962 who survived morc than a decade after renal trans-
plantation under irradiation, one from Boston and the other from Paris. 
Both received kidneys from fraternal twins. 
B. CLINICALLY hfPORTANT DRUGS 
1. Azathioprine 
A highly Significant subscquent advance was the development of 
azathioprine, a potentially radiomimetic drug with the predominant 
effect of inhibiting DNA synthesis. With this drug chronic homograft 
function could often be obtaincd without the nced for doses large 
enough to cause leukopenia. For the first time, whole-organ grafts could 
successfully be performed in dogs in a standard laboratory environment 
in which no extraordinary precautions against infection had been taken. 
In Fig. 8 is the course of recovery of a dog which had its own liver 
removed and replaced with that of a nonrelated mongrel donor. 
Azathioprine was given for only 4 postoperative months. During this 
time bone marrow depression did not develop, as shown by the normal 
white blood counts. Liver functions were essentially normal. After 4 
months all therapy was stopped. There was no deterioration in hepatic 
function. The dog is still alive almost 8 years later, not having received 
any treatment at all for more than 7 i years of this time. 
2. Cyclophosphamide 
On the basis of laboratory investigations in mice, rats or other rodents, 
and rabbits, cyclophosphamide has been thought for more than a decade 
to possess strong immunosuppressive properties. Unfortunately, when 
cyclophosphamide was tested in the dog kidney or intestinal transplanta-
tion models as an intermediate step to clinical application, no prolonga-
tion of graft survival was obtained, or else the effect was a minor one. 
92 
BILIRUBIN 
(mg%) 
SGOT 
(S-F Units) 
SGPT 
(S-F Units) 
WBe 
AZATHIOPRINE 
(mg/kg) 
THOMAS E. STARZL AND CHARLES W. PU1NAM 
I -88.6 EACH ARROW P~ S- 4 
11.5 .... 14.7 kg 
Fig. 8. Course of recovery of a dog after orthotopic homotransplantation of the 
liver. Overt clinical rejection has never been observed. Liver biopsies after 3, 6!, and 
10 months were normal. The operation was performed on March 23, 1964. The animal 
is in good health more than 8 years later. Note that immunosuppression was discon-
tinued after 4 postoperative months without subsequent deterioration of liver func-
tion. Resumption of treatment has never been required. [By permission of Surgery 
58, 131 (1965).1 
It may now be suggested that the dampening influence of the discourag-
ing canine experiments was based upon a species difference that made 
the dog an inappropriate animal to evaluate cyclophosphamide for hu-
man immunosuppression. 
Despite the experience in dogs, there has been evidence in man sup-
porting the propriety of testing cyclophosphamide for clinical whole-
organ transplantation. Some of this information came from efforts to 
promote tolerance to bone marrow grafts, as proposed by Dr. George 
Santos of Baltimore and subsequently carried out by several other work-
ers. Prodigious doses of cyclophosphamide (4.5-lO0 mg/kg per day) 
were given, but only for a few days in close temporal approximation 
to infusion of the homologous bone marrow. Although such efforts repre-
sent an essentially different therapeutic approach than that used with 
whole-organ transplantation, it is worth emphasizing that Santos' data 
on several immunosuppressive drugs have indicated that, in man, cyclo-
phosphamide should be a rival to other agents, including azathioprine. 
Almost a decade ago cyclophosphamide was given a very brief clinical 
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trial for renal homotransplantation but was promptly abandoned because 
of its toxicity. Within the past year cyclophosphamide was reintroduced 
at our institution as a substitute for azathioprine in a triple-drug com-
bination that also included heterologous antilymphocyte globulin (ALG) 
and prednisone. More than 100 human recipients of livers, kidneys, and 
hearts have been treated with this rcgimcn. The conclusion from these 
studies has been that cyclophosphamide is eqUivalent to azathioprine 
as a component of this kind of drug combination. 
3. Adrenal Corticosteroids 
Cortisone, the first major immunosuppressant to be discovered, was 
described by Billingham, Krohn, and Medawar in 1951 to delay the 
rejection of first-set skin grafts in rodents. Krohn demonstrated in 1954 
that cortisone could partially abolish a preexisting state of delayed hyper-
sensitivity in rabbits. The crucial role of prednisone in the control and 
reversal of the rejection process has been unequivocally established in 
cases of clinical whole-organ transplantation under conditions to be 
described in Section IV,C. 
4. Heterologous Antilymphocyte Serum 
Since 1965, heterologous antilymphocyte serum (ALS) and its globulin 
derivative (ALG) have received an enormous amount of attention, and 
since 1966 ALG has been used clinically with increasing frequency. ALS 
is obtained from animals (such as the horse) previously immunized 
against the lymphoid tissue of the species that is eventually to be treated 
(Fig. 9). For example, horses can be inoculated with human lympho-
cytes obtained from spleens, lymph nodes, thymuses, thoracic duct 
lymph, or tissue culture. The resulting antibody response of the horse 
can be measured by determining the ability of the serum to agglutinate 
or to lyse human white cells in vitro. After intensive immunization the 
cquine titers may rise to spectacular heights; antiwhite cell titers of 
1: 16,000 are not at all unusual. 
The serum collected from an immunized animal is a powerful immuno-
supprcssive agent when given by a varicty of routes to members of 
the lymphoid donor species. III dogs it has been possible to give as 
few as six doses of ALS or ALG to recipients of transplanted kidneys 
or livers and to have them live for as long as a year without any other 
kind of treatment. 
In patients ALG is usually given intramuscularly in combination with 
azathioprine (or cyclophosphamide) and prednisone, and its use is 
limited to the first few postoperative months. By administering ALG 
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Fig. 9. The preparation in the horse of heterologous antilymphocyte globulin for 
use in patients. (From "Christopher's Textbook of Surgery," 1968; by permission of 
W. B. Saunders Co.) 
within these guidelines, the risks of foreign protein sensitization and 
anaphylaxis are minimized. 
C. DRUG SYNERGISM 
In dogs, and probably in humans as well, consistent survival after 
renal homotransplantation is not obtainable by treating solely with any 
one of the four immunosuppressive agents described above. With trans-
plantation between nonrelated mongrel dogs, the best results have been 
with azathioprine or alternatively with ALG. Howevcr, even by using 
one or the other of thesc agents, it is possible to obtain survival exceed-
ing 100 days in only 15-30% of animals. 
Consequently, the clinical application of organ transplantation has 
been based upon the combined use of immunosuppressive measures. 
The first combination that was widely explOited was azathioprine plus 
prednisone, hereafter referred to as the "double-drug" regimen (Fig. 
10). In 1966, heterologous ALG was added to make the "triple-drug" 
regimen (Fig. 11) that has become increaSingly widely used. Finally, 
a triple-drug program in which cyclophosphamide is used in place of 
azathioprine (Fig. 12) has received an extensive clinical trial during 
the last year. 
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Fig. 10. Classic rejection crisis in a patient treated with azathioprine (Imuran) to 
which prednisone was added. Deterioration of renal function began 19 days after 
transplantation. All stigmata of rejection were present except for acute hypertension 
and weight gain, which were successfully prevented by medical treatment. Acti C, 
actinomycin C; LN, left nephrectomy at time of transplantation; Rl\', right nephrec-
tomy. [By permission of Surg. GlJnecol. Obstrd. 117,38.5 (1963).] 
V. Changing Host-Graft Relationships 
Since each of the major systemic immunosuppressive agents mentioned 
above can cause general immunological crippling, it has been customary 
to categorize as nonspecific all the treatment protocols (Figs. 10-12) 
in which they haw been employed. The implied criticism of using a 
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Fig. 11. The postoperative course of a patient who received ALG before and for 
thc first 4 months after renal homotransplantation. The donor was an older brother. 
There was no early rejection. Prednisone therapy was started 40 days postoperatively 
because of high rises in the serological titers which indicated a host response against 
the injected foreign protein and which warned against a possible anaphylactic rc-
action. Note the insidious onset of late rejection after cessation of globulin therapy. 
This was treated by increasing the maintenance dose of steroids. [By permission of 
Surg., Gynecol. Obstet. 126, 1023 (1968).J 
sledge hammer where a therapeutic scalpel would be preferable is not 
without justification. 
Nevertheless, there has been for nearly a decade an impressive body of 
information indicating that whole-organ homotransplantation with such 
therapy can eventually lead to selective abrogation of the host rejection 
response, that the success with which this can be done is related among 
other things to histocompatibility factors, and that the degree to which 
it is achieved is the most important determinant of prognosis in any 
given case. Appreciation that the immunological relation of the graft 
to the host is a fluid rather than a fixed one adds an important dimension 
to the consideration of any kind of immunosuppression. 
A. REJECTION AND ITs REMISSION 
There are two clinically identifiable phases in the chain of events 
under discussion. The first consists of an attack by the host's immune 
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Fig. 12. The first 60 days after the transplantation of a kidney from a mother to 
her daughter. Although the rejection crisis after 1 week was a severe one, it was 
easily and completely reversed. Note that leukopenia was never produced by the 
daily doses of cyclophosphamide which were usually between 0.5 to 1.0 mg/kg per 
day. ALG, Horse antilymphocyte globulin; BUN, blood urea nitrogen; CCr, creatinine 
clearance; WBC, white blood cell count; arrow, 625 mg methyl prednisolone intra-
venously. [By permission of Surg., Gynecol. Obstet. 133, 981 (1971).J 
defenses upon the new organ, usually within a few days or weeks after 
its transplantation. The vigor of the process is highly variable, as judged 
by the magnitude of the changes caused in the morphology and function 
of the homograft. 
\Vhether severe or mild, the intensity of the acute rejection ultimately 
tends to abate in the second phase in many cases, particularly if short-
term increases in immunosuppression are instituted. However, the force-
fulness of the rejection may diminish even without making such changes 
in therapy, or occasionally in animals that have not received any treat-
ment at all (see Section III ) . 
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1. Human Renal Recipients 
The remission of rejection was not convincingly demonstrated in ani-
mals until it was observcd following clinical renal homotransplantation. 
In retrospect, it is probable that the two earliest successfully treated 
human recipients of fraternal hvin transplants alluded to earlier passed 
through mild and spontaneously reversible immunological crises after 
having been submitted to total body irradiation. How€ver, in both the 
Boston and Paris twin cases, it could be speculated that the long survival 
may have been partially due to a high-grade although incompletc pre-
existing tolerance such as that seen in the freemartin cattle Siblings 
that have had a shared placental circulation during gestation (Section 
IV,A). 
Strong indications that rejection was a highly controllable and regu-
larly reversible phenomenon, and that it was often followed by a state 
of relative "host-graft nonreactivity," came from observations of a num-
ber of nontwin recipients who were treated in late 1962 and early 1963. 
Many of these patients had clear-cut rejections commencing from a few 
days to several weeks after the operation. The process was regularly re-
versed by the addition of massive doses of prednisone to the preexisting 
therapy with azathioprine (Fig. 10). Then, within a surprisingly short 
time, it became possible to drastically reduce the steroids that initially had 
been necessary to rescue the grafts (Figs. 10, 12, and 13). In several 
instances the patients were soon returned to treatment only with 
azathioprine, the agent that at the beginning had not been capable 
of preventing an acutc rcjection crisis (Fig. 13). Many of these patients 
are Still alive 9 or 10 years later. 
There is no point in commenting further on the fully accepted fact 
that kidney rejection can undergo remission beyond noting that such 
an occurrence is uncommon in dogs and probably also in humans if 
immunosuppression is not increased. It is also worth mentioning that 
the central role of steroids in promoting this event in clinical practice 
was probably predictable on the basis of Krohn's report of 1954, which 
showed that preexisting graft sensitization could be erased in rabbits 
with steroids. However, the practical implications of this finding were 
not appreciated until many years later. 
2. Animal Recipients 
Although recovery of a rejecting kidney graft cannot usually be ex-
pected unless treatment is intensified, it was pOinted out earlier that 
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Fig. 13. The first 2 postoperative years of the same patient whose early course is 
displayed in Fig. 10. Note that steroid therapy was discontinued after 5 months, and 
that eventually the maintenance azathioprine treatment was about half the daily 
dosage as that which at the outset did not prevent the onset of a moderately severe 
rejection. [By permission of Ann. Surg. 162,749 (1965).J 
spontaneous reversal sometimes can occur in both dogs and pigs and 
particularly with liver transplantation in the latter species. With resolu-
tion of thc rejection process, abnormalities both in the graft function 
tests and organ blood flow tend to return toward, although often not 
completely to, normal. 
In both treated and untreated animals, there have been histopatho-
logical studies supporting the idea that an initial forceful host attack 
can subsequently tend to exhaust itself or at best to become less effec-
tive. Initially, the homografts become invaded with mononuclear cells, 
even in some animals not undergOing biochemical and clinical signs of 
rejection. In surviving animals the infiltrate in various kinds of grafts 
may decrease in density or disappear. Subsequently, the predomi-
nant morphological changes usually become those of repair and/ or 
regeneration. 
The foregoing comments should not be construed as suggesting that 
the desired change in the host-graft relationship is dependent upon an 
overt rejection crisis. Most of the animal recipients of kidneys or livers 
in which a more-or-Iess completely "tolerant" state developed, as defined 
by the ability to avoid therapy, or to discontinue it, have been those 
in which diagnosable acute rejection had either been very minor or 
had not occurred at all. In these experiments the first wave of immuno-
logical reaction had apparently becn insufficient to cause significant 
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Fig. 14. A patient in whom a fully developed rejection episode did not occur after 
transplantation from a non twin sibling donor. Protracted eosinophilia was observed, 
however, lasting for more than 1 month. In addition, the patient had a febrile crisis 
for which no explanation could be found. It was at first thought that the fever was 
due to infarction of the testis which had occurred on the side of transplantation, and 
later that a deep wound infection might be present. The patient was first subjected 
to left orchiectomy, and later to wound reexploration. Ultimately, there was defer-
vescence without provision of specific therapy. No drug other than azathioprine was 
ever employed. Bilateral nephrectomy and splenectomy were perform cd at the time 
of transplantation. The operation was on July 5, 1963. Almost 81 years later, the 
homograft is still providing perfect function. [By permission of Surgery 56, 296 
(1964 ).J 
deterioration of homograft function. There have been well-documented 
examples of this kind of "subclinical rejection" in patients (Fig, 14). 
B. MECHANISMS OF GRAFT ACCEPTANCE 
Although it has been well established that a homograft may come 
to be more or less tolerated in its new host, the explanation for the 
privileged status is not accepted with any more unanimity today than 
it was 5 years ago. One of the reasons probably is that more than one 
immunological pathway may be involved. 
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1. Specific Immunological Tolerance 
It is almost certain that the continuous presence of a transplanted 
organ in a host being treated with immunosuppressive therapy often 
leads to a selective loss of responsiveness to the antigens of the homo-
graft (tolerance). The evidence that chemotherapy can be used for the 
induction of narrow-range tolerance is unequivocal. The literature on 
this subject is not reviewed here since it has been well summarized 
by Dr. Robert Schwartz, who was the first to call attention to this possi-
bility. Suffice it to say that azathioprine, 6-mereaptopurine, amethopterin, 
cyclophosphamide, and even total body irradiation can be used to 
promote specific tolerance, providing the antigen in question is admin-
istered in an appropriate dose and in close temporal approximation to 
the immunosuppressive treatment. 
One of thc theorics advanced by Schwartz to explain the specific 
effect of chemotherapy under thesc circumstances is depicted in Fig. 
15. The illustration suggests that a clone of lymphocytes which presum-
ably have an active metabolism as the result of stimulation by antigen 
should be differentially susceptible to antimetabolites. 
It is interesting how compatible this hypothesis is with the events 
that actually take place after transplantation. Temporally, the first evi-
dence of adaptation is often coincident with reversal of the rejection 
crisis. It has been noted that both the reversal of rejection and graft 
acceptance can occur in most cases without the necessity for even 
temporary suppression of the total white blood count below normal 
levels. Here, the peripheral white cells as well as the humoral antibodies 
with which the graft is in constant contact appear to have ultimately 
lost at least part of their capacity to injure the foreign tissue. In these 
cases the ultimate lymphocyte population seemed to be inactive, at least 
in a relative sense, against the renal antigen. It is tempting to believe 
that immunosuppressive therapy caused a progressive attrition of those 
cells that were immunologically sensitized against the homograft antigen 
and that the replacement cells had an absent or reduced memory of 
the alien tissue. 
The concept of "clone stripping" in this scheme is consistent with 
the cyclic phenomena that characteristically occur after whole-organ 
transplantation both in treated animals and man. With the existence 
of very close biological compatibility between donor and recipient, it 
could also explain the apparent acceptance of weakly antigenic homo-
grafts as has apparently occurred in unmodified pigs. Under either set 
of circumstances, the sequence might be analogous to that demonstrated 
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Fig. 15. Hypothetical mechanisms by which nonspecific immunosuppression may 
lead to selective abrogation of the host immune response. Special susceptibility to 
these agents of a fraction of the lymphoid population could lead to exhaustion of a 
clone, hence tolerance. Since maintenance of such cell lines even in adult life is 
apparently thymus-dependent in experimental animals, thymectomy would be ex-
pected to aid the process; this appears to be true in rodents, but such an elTect of 
thymus removal has not been detected in dogs or humans. A possible protective role 
is also shown for immunoglobulins elaborated by the replicating cells. Conceivably, 
the antibodies could act either at the site of the antigen (enhancement) or by 
affecting the macrophage processing of the antigen. (From Experience in Hepatic 
Transplantation; by permission of \V, B. Saunders Co., 19G9.) 
by Brent and Gowland in which tolerance in mice was preceded by 
a transient period of sensitization (Fig. 16). 
Nevertheless, there has been a widespread reluctance to believe that 
speCific immunological tolerance has been produced with the immuno-
suppressive regimens described in Section IV,C after either experimental 
or clinical whole-organ transplantation. The article most often quoted 
as contravening this possibility is that of Dr. Joseph Murray and his 
colleagues, which appeared in a 1964 issue of the Annals of Surgery, 
despite the fact, as the authors took pains to make clear, that the evi-
dence in the report was inconclusive and involved only two canine ex-
periments of a potentially crucial nature. These two dogs had been 
given renal homo grafts 9 and 18 months preViously and had received 
long-term therapy with one of the purine analogs. Throughout the post-
operative course renal function appeared from the published charts to 
have been unstable. Moreover, it was deteriorating at the time the other 
kidneys from the original donors were transplanted; in both instances 
the blood urea nitrogen had become Significantly elevated by the time 
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Fig. 16. The experiment of Brent and Gowland showing the induction first of 
sensitization and then of tolerance in mice treated with donor-specific spleen cells. 
The survival times of subsequently transplanted skin homografts are plotted 
against the number of preconditioning injections. Note that a small number of injec-
tions sensitized the animals, but that tolerance developed when the treatment was 
more protracted. The analogy between these findings and those of a reversible aeute 
rejection crisis is evident. [Modified from an illustration in Nature (London) 196, 
1298 (1962).] 
of the retransplantations. The second organs were rejected after 23 and 
3 days, respectively. It could be persuasively argued that there was 
not good justification to believe that the first kidneys in these animals 
were well tolerated, in which case there would be little reason to antici-
pate that the second organs would be accepted kindly. 
To date, few investigations have been carried out in human recipients 
of renal homo grafts surviving for prolonged periods to establish the 
presence or absence of specific immunological tolerance to their donor 
tissue. One of the reasons has been the potential risk that could attend 
some of the testing that might be done, such as skin transplantation 
from the original renal donor. However, it is worth mentioning that 
Drs. Fritz and Marilyn Bach of :\1adison, \Visconsin, performed mixed 
lymphocyte culture examinations from the peripheral blood of a group 
of our recipients and their donors, 2 to 4 years after transplantation, 
as well as upon some donor-recipient pairs of Dr. John Najarian's 
Minnesota series. In several cases in whieh clear donor-recipient histo-
incompatibilities were detectable by serological typing, the Bachs found 
that the recipient lymphocytes no longer underwent blast transformation 
when exposed to killed donor white cells, although they reacted vigor-
ously to third-party lymphocytes. The findings were interpreted as indi-
cating specific acquired immunological tolerance. 
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2. Enhancement 
Many years ago it was shown by Kaliss that homo grafts of tumor 
tissue can be protected by the presence of certain kinds of antigraft 
antibodies. It is conceivable by a feedback mechanism that the same 
thing occurs under the conditions of whole-organ transplantation. The 
process could be envisioned as shown in Fig. 15, whereby immunoglobu-
lins synthesized by the activated clone return to the target tissue and 
coat or protect it in some other way. 
Certainly, it has been possible to demonstrate antigraft antibodies 
in the sera of patients carrying chronically functioning and apparently 
well-tolerated kidneys. Using an antiglobulin consumption test, Dr. Yoji 
Iwasaki of Colorado and also Dr. Felix Rapaport of New York showed 
that the serum of most of the tested human recipients contained 7 S 
immunoglobulins which could be selectively absorbed by the nucleated 
cells of the original donor. Moreover, there have been numerous reports 
of more-or-less extensive immunoglobulin deposition, as detected by 
immunofluoresccnce techniques, in long-functioning human kidney trans-
plants. By and large, however, the latter finding does not connote a 
favorable prognostic sign but rather the converse. 
The mechanism of enhancement may explain the kind of observation 
originally made by Woodruff and Woodruff and termed by them 
"adaptation." In their experiments with guinea pigs, bits of homograft 
tissue were implanted in the anterior chamber of the eye and later 
transferred to a subcutaneous location. There rejection occurred very 
slowly or not at all. In contrast, subcutaneously placed thyroid from 
the same donor was repudiated promptly. Some of Murray's experiments 
with canine renal transplantation were deSigned along similar lines and 
yielded comparable results. He showed that a secondarily placed kidney 
could undergo rejection while the contralateral organ that had been 
transplanted earlier from the same donor continued to function. The 
differential ability of the first kidney to resist destruction was not due 
to a change in its genetic character since it could also function when 
replaced in the original donor. The same general observations had been 
made in 1954 by Weber, Cannon, and Longmire, who used skin grafts 
. in chickens. 
Recently, Hellstrom and Hellstrom of Seattle have published with 
Pierce and Marchioro some observations that may make the term "en-
hancement" somewhat less mystical than it has been in the past. They 
showed that the sera of patients with well-accepted renal homo grafts 
contain antibodics capable of "blocking" the cytotoxic action of recipient 
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lymphocytes upon donor tissues. Further characterization of these block-
ing antibodies and their biological signficance is one of the most active 
areas of applied immunolOgical research. 
It is not necessary to believe that enhancement must exert its influence 
in an isolated way, as the recent studies of Frank Stuart of Chicago 
have made clear. He showed that the survival of renal homo grafts in 
rats could be more consistently obtained with the combinatiQn of toler-
ance induction plus the administration of enhancing antibodies than 
when either approach was used alone. 
3. Failure of Antigen Processing 
There is the added possibility that a defect in antigen processing 
by the reticuloendothelial system could be responsible for graft accept-
ance, a concept for which there is not yet any firm evidence. However, 
it is known that antisera can under certain circumstances markedly and 
specifically inhibit the responsiveness to the antigen recognition for long 
periods. The way in which an analogous sequence of events could be 
hypothetically injected into the picture after organ transplantation is 
shown in Fig. 15. 
VI. Graft Pretreatment 
Many of the problems of organ transplantation could be minimized 
if it were possible to mitigate graft rejection by modifying the trans-
planted tissue rather than the host immunological response. Efforts to 
achieve this objective have been unsuccessful with occasional possible 
exceptions. 
A. THE REMOVAL OF PASSENGER LYMPHOCYTES 
In 1957, Dr. George Snell suggested that donor leukocytes in grafts 
might play a significant role in eliciting an immune response from the 
recipient. Within the last 2 years, Dr. David Steinmuller and his asso-
ciates at the University of Utah have proved that Snell was right. They 
showed that removal by one means or other of the lymphoid tissue in 
grafts apparently reduc~s the antigenicity and thereby considerably pro-
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longs survival. Forms of donor or graft pretreatment that have been 
shown to be effective include irradiation or the administration of cyclo-
phosphamide or ALS. 
So far, there have not been efforts to exploit this therapeutic approach 
clinically. However, if the concept is sound, efficient removal of 
passenger leukocytes is certain to have important clinical implications. 
B. RNA PERFUSION 
Some of the most intriguing experiments with organ pretreatment 
were described by Jolley, Hinshaw, and Peterson of Lorna Linda, Cali-
fornia. They reported that rabbit skin grafts first immersed in homolo-
gous ribonucleic acid (RNA) and then transplanted to recipient animals 
which were given intravenous RNA survived four times longer than 
controls. The role of the preliminary soaking was not analyzable in 
these experiments, but these investigators also reported that human skin 
homografts subjected to RNA soaking only had unusually protracted 
viability when placed upon patients with burns. Similar findings have 
been reported in mice. 
Attempts to "pretreat" whole-organ homo grafts have been made in 
dogs by Dr. Carl Groth and his associates. They perfused kidneys for 
about 30 minutes with RNA prepared by phenol extraction from the 
spleens of the prospective recipients ("autologous" RNA) or other dogs 
("homologous" RNA). After transplantation to unmodified recipients, 
about one-fourth of these life-sustaining organs had prolonged homograft 
viability. Maximum survival of recipients subjected to simultaneous re-
moval of their own kidneys was more than 4 months. The mean survival 
in a group of 40 recipients was more than 20 days, as opposed to ap-
proximately 10 days in 30 control animals. Furthermore, thcre were 
7 homo grafts of the 40 that had no histological evidence of rejection, 
whereas all the control homo grafts had the typical findings of unmodified 
rejection. 
It is not yet certain that the foregOing findings represented more than 
an experimental artifact, since a logical explanation for the surprising 
results was not available and because the degree of homograft protection 
was so relatively limited that its statistical significance in terms of survival 
was marginal. It will be of interest in laboratory experiments first to 
confirm these observations and then to determine whether or not this 
kind of graft conditioning can be advantageously combined with effec-
tive host immunosuppression. 
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C. EXPOSURE TO ENHANCING ANTffiODY 
As described earlier (Section II,C,2), the serum of an animal or pa-
tient sensitized to a given donor can precipitate the hyperacute rejection 
of a kidney from that donor. If the responsible antidonor antibodies 
are digested with pepsin, they may still attach to the antigen, but such 
altered immunoglobulins do not bind complement and are no longer 
injurious. Richard Wilson of Boston and several other investigators have 
been interested in the perfusion of homo grafts with digested cytotoxic 
antibody in the hope that the digested F( ab) 2 fragments may lead to 
"local" enhanccment. In vicw of the potential harm that could result 
in the event of an immunological accident, very complete experimental 
evaluation will be required before this approach can be tried clinically. 
VII. Histocompatibility Typing in Patients 
In Chapter 7 is found a description of what has been thought to 
be the major human histocompatibility system (HL-A). The antigens 
of this system have been measured in laboratories from one end of 
the earth to the other. The reagents used for typing have been lympho-
cytotoxin-rich human isoimmune antisera obtained from persons who 
have been sensitized accidentally or deliberately to white cell antigens. 
The cytolysis of test lymphocytes by such antisera indicates the 
presence of the same or a similar antigen as that which originally sensi-
tized the serum donor. Failure of such a reaction implies the absence 
of the antigen. \Vhen the lymphocytes of both the donor and recipient 
react in the same way to a given antiserum, identity of that antigen 
is said to be present. The absence of an antigen in a donor that is 
present in a recipient is defined as compatibility. When an antigen is 
found in the donor lymphocytes but not in those of the recipient, a 
mismatch exists. Identity of antigens is preferable, compatibility is the 
next most satisfactory condition, and the least desirable is an overt 
mismatch. 
The present view of the HL-A system is that there are two major 
loci on the same chromosome and that each locus has two antigens 
(alternating allele hypothesis). The possibility of a perfect match of 
all four antigens between randomized members of the nonrelated popula-
tion is statistically rather remote, substantially less in most cases than 
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the chance of having all these antigens mismatched. It can be appreci-
ated from these considerations that major logistical problems would have 
to be dealt with if a well-matched cadaveric organ were to be sought 
for a given recipient, since the chance of obtaining a four-antigen or 
"full house" match would ordinarily be less than 1%. 
The foregoing statistical factor would be a deterrent enough to the 
hope of regional or national tissue-matching and organ-sharing schemes. 
Even more serious is the fact that correlations between the quality of 
HL-A tissue matching and the outcome after renal, hepatic, and cardiac 
transplantation have so far not been significant in large and well-studied 
series such as our own and those of Murray (Boston), Hamburger 
(Paris), Hume (Richmond), Najarian (Minneapolis), and Kountz (San 
Francisco) . 
In our clinics HL-A typing has been carried out in all cases since 
1964. The clinical and histopathological observations were then com-
pared with the widely used A-E, F-antigen match classification popular-
ized by Dr. Paul Terasaki of Los Angeles. With this system the letters 
are a statement in code about the compatibility, incompatibility, or 
identity of the HL-A antigens. 
Following intersibling transplantation it is encouraging that histocom-
patibility matching by this method correlates at least partially with the 
outcome. Specifically, the designation of an A (good) match endows 
a slight advantage in terms of survival and quality of homograft function, 
as well as a highly significant advantage in terms of the histopathological 
appearance of the kidneys at varying times postoperatively. In practical 
fact, the designation of an A match in Sibling cases usually is an indica-
tion that the donor and the recipient both have the same two histocom-
patibility haplotypes, one from each parent, and therefore have achieved 
identity of the HL-A antigens; for the HL-A chromosome it could be 
said that there is genotype as well as phenotype identity (see Chap-
ter 7). 
In contrast, Significant clinical or histopathological correlations could 
not be demonstrated between the phenotype grades and the results with 
the parent-to-offspring transplantations. With this familial combination 
half of the HL-A antigens of the donor (one haplotype) are by definition 
identical to those in the recipient. The remaining 50% of HL-A antigens 
are in essence unrelated. It is the unrelated half of the donor-recipient 
genetic mass that finds expression in the A-E score. 
In the parental cases there could be several explanations for the failure 
to find significant relationships between the alphabetical grades and 
survival, function, or histopathology. The possibility that HL-A antigens 
are irrelevant to histocompatibility cannot be seriously entertained in 
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view of the evidence to the contrary cited above in connection with 
sibling cascs and in view of supporting evidence from other kinds of 
studies. A second possibility is that "immunological artifact" caused by 
the transmission of preexisting host glomeruloncphritis to the transplants 
is responsible (see Section n,B). However, in our case material the 
latter factor alone could not explain all or even the majority of the 
poor correlations. It could also reasonably be speculated that: (1) the 
completeness and I or accuracy with which HL-A phenotypes currently 
can be measured is substantially less than is generally realized; (2) 
significant and presently undetected histocompatibility loci exist on 
other than HL-A chromosomes; (3) variablc host immunological reac-
tivity in different patients is comparable in importance to the antigen 
match in determining the outcome; or, (4) host presensitization to anti-
gens present in the homografts jeopardizes the outcome ill some in-
stances but is not always recognized as a factor. 
Whatever the explanation, the experience with the parental cases 
reaffirms a finding first noted several years ago. In many of these same 
patients, as well as in mismatched siblings, it was learned that immuno-
suppressive treatment could very often override significant or even ap-
parently ominous incompatibilities, with subsequent renal grafts surviv-
ing for many years. The durability of related but mismatched kidneys 
has become even more evident with the longer follow-ups, now as long 
as 9 years. As a consequence, our policy continues to be to accept 
parental donors despite the fact that they may be badly matched. More-
over, siblings and other relatives are not arbitrarily excluded from giving 
kidneys simply because of antigen incompatibilities, although an effort 
is usually made in these circumstances to determine if the donor and 
recipient share one HL-A haplotype and are therefore genetically similar 
to a parent-offspring combination. If only one donor is available, the 
only absolute immunological contraindication to intrafamilial trans-
plantation in our center is the demonstration of preformed antidonor 
humoral antibodies. 
Since the A-E grades fail to conform to any identifiable spectrum 
of outcome after the parent-to-offspring transplantations, it is hardly 
surprising to find the same lack of correlation within the much less 
fortunate group of patients who receive nonrelated kidneys and who 
tend to die or lose their transplants at a higher rate both early and 
late after operation. Reducing the risk in this kind of case has become 
one of the great challenges of applied immunology. It remains to be 
seen whether or not more assiduous application of serological tissue-typ-
ing techniques will be instrumental in improving the outlook for the 
nonrelated recipient. If so, it now seems certain, in view of the negative 
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results thus far obtained, that improved methods of interpretation must 
be cvolved or else that nearly perfect matching of a truly complete 
set of antigens will be required. 
Before concluding these necessarily brief comments about tissue typ-
ing, it should be cmphasized that methods of matching are available 
other than the serological ones just discussed. It is probable that 
a direct cross-match technique, such as the mixed lymphocyte culture 
method of Bach and Hirschhorn, would be much more discriminating. 
However, the Bach-Hirschhorn approach requires the bctter part of a 
week to be completed, a time that is much too long to permit practical 
application in most cadaveric cases at the present time. However, it 
is also obvious that a major advance in organ banking would permit 
thc application of such direct measures of histocompatibility. Thus 
progress in long-range organ preservation would not only cut the waste 
of cadaveric organs that is inevitable today, but it would also allow 
the use of more predictive techniques of tissue typing. 
VIII. Is Clinical Organ Transplantation Practical? 
It is not the purpose of this article to present clinical data. Neverthe-
less, a brief statement is in order about what has bcen achieved so 
far. The modern era of whole-organ transplantation began in late 1962 
and early 1963, from which era there are still about two dozen patients 
living after having had continuous subsequent function of their trans-
plants. Since this timc, thousands of patients have benefitted from renal 
homotransplantation and have thereafter undcrgone relatively complete 
social and vocational rehabilitation. This has been particularly true in 
recipients of consanguincous grafts, who now can cxpect to survive the 
first post-transplantation year at the rate of approximately 90%. It is 
less true of recipients of unrelated (cadaveric) transplants in whom only 
60 or 70% of grafts function for as long as a year. 
In successfully treated paticnts there has not been the theoretical 
impasse referred to in Section IV,A, namely, having an unacceptable 
susceptibility to infection. These patients have not reqUired a controlled 
bacteriological environment after discharge from the hospital. All that 
is necessary is that they seek prompt medical attention if they develop 
any kind of infectious disease. Then they can usually be treated success-
fully with antibiotics or other standard measures. The rcason why this 
kind of happy outcome is so often possible is that complete host crippling 
is not required to achieve "graft acceptance," as was explained in Section 
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V. Thus although there is always an increased rise of infection, this 
is not so grave as to vitiate the value of the procedures. 
The other highly identifiable risk of chronic immunosuppression is 
an increased incidence of de novo malignancy. From the premises of 
Burnet and Thomas regarding thc immunological control of malignancy 
(surveillance hypothesis) it could have been predicted, and was, that 
an increased incidence of de novo tumors would develop in people 
with naturally occurring immunological defiCiency diseases or in patients 
whose immunc reactivity was delibcrately depressed in order to permit 
their acceptance of organ homografts. The hazard of malignancy conse-
quent to spontaneous immunological deficiency is so well known from 
Dr. Robert Good's surveys that it is not reviewed here. 
Analogous data in iatrogenically immunosuppressed transplant recipi-
ents was not publicized until the spring of 1968. Since then, more than 
60 examples of new malignancy in transplant recipients have been re-
corded in an informal registry maintained at the University of Colorado. 
More than one-third of thC'se neoplasms have been of the lymphoreticular 
system. The main practical consequencc of this information is that 
chronically immunosuppressed patients should be watched closely for 
any evidence of new growth. Early diagnosis is especially important 
since many recipients with this complication have now been cured with 
standard means of treatment including excision, irradiation, and even 
chemotherapy-especially if this therapy is combined with a lightening 
of immunosuppression. 
Transplantation of organs other than the kidney has not yet become 
comparably practical in spite of the fact that the feaSibility stage of 
liver, cardiac, and lung transplantation has already been passed. There 
are several reasons for the high failure rate after transplantation of the 
extrarenal organs, but for the most part these reasons are nonimmuno-
logical. They include greater technical difficulties; the lack of artificial 
organs comparable to renal dialysis which could tide the hepatic, cardiac, 
or pulmonary patient over transient periods of poor function; and even 
the lack of discriminating techniques to diagnose rejection in its early 
and most reversible phases. 
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